Reviewing Arotech (ARTX) & Its Peers

Arotech (NASDAQ: ARTX) is one of 62 publicly-traded companies in the “AEROSPACE/DEFENSE” industry, but how does it contrast to its competitors? We will compare Arotech to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

22.3% of Arotech shares are owned by institutional investors. Comparatively, 56.3% of shares of all “AEROSPACE/DEFENSE” companies are owned by institutional investors. 9.2% of Arotech shares are owned by company insiders. Comparatively, 8.7% of shares of all “AEROSPACE/DEFENSE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Arotech and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Arotech $98.72 million $3.83 million 21.33
Arotech Competitors $8.26 billion $580.70 million 21.85

Arotech’s competitors have higher revenue and earnings than Arotech. Arotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Arotech and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arotech 3.88% 5.98% 3.61%
Arotech Competitors -0.95% -265.63% 8.25%

Risk & Volatility

Arotech has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Arotech’s competitors have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Arotech and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arotech 0 0 1 0 3.00
Arotech Competitors 372 2195 2980 101 2.50

Arotech currently has a consensus target price of $4.50, suggesting a potential upside of 40.63%. As a group, “AEROSPACE/DEFENSE” companies have a potential upside of 5.79%. Given Arotech’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Arotech is more favorable than its competitors.

Summary

Arotech beats its competitors on 7 of the 13 factors compared.

About Arotech

Arotech Corporation is a defense and security products and services company, engaged in providing interactive simulation for military, law enforcement and commercial markets, and batteries and charging systems for the military, commercial and medical markets. The Company operates through two segments: Training and Simulation Division, and Power Systems Division. The Company’s Training and Simulation Division develops, manufactures and markets multimedia and interactive digital solutions for engineering, use-of-force training and operator training of military, law enforcement, security, emergency services and other personnel. The Company’s Power Systems Division provides battery solutions, energy management and power distribution technologies and product design and manufacturing services for the aerospace, defense, law enforcement, homeland security markets, and it manufactures and sells rechargeable batteries for defense and security products and medical and industrial applications.

Receive News & Ratings for Arotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Financial Comparison: Yamaha Motor  vs. Fox Factory
Financial Comparison: Yamaha Motor vs. Fox Factory
Portland General Electric  Scheduled to Post Quarterly Earnings on Friday
Portland General Electric Scheduled to Post Quarterly Earnings on Friday
NovaBay Pharmaceuticals, Inc.  Receives Consensus Recommendation of “Hold” from Analysts
NovaBay Pharmaceuticals, Inc. Receives Consensus Recommendation of “Hold” from Analysts
Amarin Co.  Given Consensus Recommendation of “Hold” by Analysts
Amarin Co. Given Consensus Recommendation of “Hold” by Analysts
Polymetal International PLC  Receives Average Rating of “Hold” from Analysts
Polymetal International PLC Receives Average Rating of “Hold” from Analysts
Q1 2018 Earnings Estimate for Energen Issued By Imperial Capital
Q1 2018 Earnings Estimate for Energen Issued By Imperial Capital


© 2006-2018 Ticker Report. Google+.